Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amivantamab + cetrelimab
- Development stage
- Phase 2
- Lead developer
- Johnson & Johnson
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Amivantamab + cetrelimab** is an investigational combination therapy for cancer, currently studied primarily in metastatic non-small cell lung cancer (NSCLC). Amivantamab is a fully human bispecific monoclonal antibody that targets both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET), blocking their signaling and mediating antibody-dependent cell-mediated cytotoxicity (ADCC). Cetrelimab is a programmed cell death protein 1 (PD-1) checkpoint inhibitor monoclonal antibody, enhancing the immune response against tumor cells. The combination is designed to simultaneously inhibit oncogenic signaling and reinvigorate anti-tumor immune responses. Both agents are developed by Janssen, and combination studies are primarily in early clinical phases in NSCLC, particularly for tumors characterized by EGFR mutations. Clinical trial data indicate potential synergistic efficacy and modulation of tumor resistance pathways by dual targeting EGFR/MET and PD-1[1][4][7].
- Other names
- amivantamab + cetrelimab
02
Targets
EGFR (Epidermal growth factor receptor)MET (Mesenchymal-epithelial transition factor receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on amivantamab + cetrelimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amivantamab + cetrelimab.